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boost dose), para-aortic region alone (para-aortic recurrence, 
N=5, all with boost dose). Robust IMPT (minimax method) and 
20-beam IMRT plans were generated with an in-house 
developed system for automated treatment planning. 
Prescription dose was 48.6 Gy with or without a simultaneous 
integrated boost to 58.05 Gy. IMPT and IMRT plans were 
made for wide (15 mm primary CTV/7 mm nodal CTV) and 
small (5/2 mm) CTV-PTV margins. IMPT plans included range 
robustness of 3% and setup robustness of 2 mm assuming 
online setup correction and adaptive radiotherapy. Relevant 
dose-volume parameters of OARs were used to compare both 
techniques. 
 
Results: IMPT reduced the dose in all OARs for similar target 
coverage (>99%). The benefit of IMPT was higher in the lower 
dose region than in the higher dose region. Figure 1 compares 
OAR dose-volume parameters per patient. For treatment of 
the pelvic region, the dose in pelvic bones was on average 
27% lower with IMPT; and in femoral heads 5% lower. For 
treatment of pelvic and para-aortic region, kidney and spinal 
cord dose was lower for IMPT (left kidney 1.1 Gy vs 7.8 Gy; 
right kidney 2.4 Gy vs 11.8 Gy; spinal cord 14.5 Gy vs 28.0 
Gy). For the para-aortic region alone an important advantage 
in favour of IMPT was seen (left kidney 4.4 Gy vs 38.6 Gy; 
right kidney 0.5 Gy vs 5.8 Gy; spinal cord 29.2 Gy vs 39.7 Gy), 
see Table 1. For all target volumes clinically relevant 
reductions in V15Gy for the bowelbag were found, reducing 
V15Gy by 153 cc, 1231 cc, and 523 cc, respectively. 
Differences in dose to most OARs were similar for wide and 
small margins, while the advantage of IMPT was more 
pronounced for rectum, bladder, and sigmoid using small 
margins. 
 
 
 
Conclusion: For all gynaecological target volumes, IMPT 
reduced the dose to all OARs compared with IMRT, mainly in 
the lower dose region and for both wide and small margins. 
Considerable reduction of the bowel volume receiving 15 Gy 
or more was seen. The greatest and clinically relevant 
advantage of IMPT was found for treatment of macroscopic 
disease in the para-aortic region, justifying the use of proton 
therapy for this indication. 
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Purpose or Objective: Proton beam therapy represents a 
promising modality for left breast irradiation due to 
negligible dose to non-target volume, as heart and lung. 
However skin toxicity and poor cosmesis inherent to protons 
physical properties are of major concern. Radiation-induced 
skin toxicity (RIST) is a side effect impacting on the quality of 
life in breast cancer patients treated with radiation therapy. 
Purpose of the present study is twofold: a) to develop a 
normal tissue complication probability (NTCP) model of 
severe acute RIST in BC patients treated with conventional 
three-dimensional conformal radiotherapy (3DCRT) and b) to 
use the implemented skin NTCP model to guide breast proton 
therapy plan optimization. 
 
Material and Methods: We evaluated 140 consecutive BC 
patients undergoing 3DCRT after breast conserving surgery in 
a prospective study assessing acute RIST. Acute RIST was 
classified according to the RTOG scoring system. Dose-surface 
histograms (DSHs) of the body-structure in the breast region 
were extracted. DSHs of the body were considered as 
representative of the irradiation in epidermis and dermis 
layers and extracted by an in-house developed library using 
the relative complement in the body of its 3D erosion defined 
by a spherical structuring element of radius r = 3 mm 
(assumed as mean skin thickness). On such shell, the absolute 
dose-volume histogram was regularly computed and then 
divided by r to obtain the DSH. NTCP modeling by Lyman-
Kutcher-Burman (LKB) recast for DSHs and using bootstrap 
resampling techniques was performed. Five randomly 
selected left BC patients were then replanned using proton 
pencil beam scanning (PBS). PBS plans were obtained to 
ensure appropriate target coverage (90% 50 Gy(RBE) 
prescription dose to the 90% breast) and heart-lung sparing. 
Different planning objectives for skin were used (Table 1) and 
two different beam set-ups were tested. The proton plan 
body DSHs were extracted and the corresponding NTCP values 
calculated. 
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Results: By the end of 3DCRT, severe (RTOG G3 vs. G0-2) 
acute RIST was found in 11 out of 140 (8%) patients. Using 
DSHs for LKB modeling of acute RIST severity (estimated 
model parameter: TD50=39 ± 4 Gy, m=0.13 ±0.08, n=0.36 
±0.05) a good prediction performance was obtained (Rs= 0.3, 
AUC= 0.8, p=0.003). When used to guide parameter choice in 
proton PBS optimization, our NTCP model suggests that the 
probability of having acute RIST can be on average lowered 
by a factor 2.7 using a single oblique beam or even by a 
factor 6 with a tangential-beam set up (Table 1 and Figure 
1a) at negligible expense of target coverage (Figure 1b). 
 
 
 
Conclusion: Robust LKB NTCP model with a good prediction 
performance for acute RIST can be derived using the body 
DSHs of the irradiated area. The obtained skin NTCP 
represents a valuable tool for breast proton plan optimization 
and evaluation in order to reduce the risk of acute skin 
toxicity. 
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Purpose or Objective: An elevated risk of secondary cancer 
(SC) has been observed in prostate cancer patients following 
radiotherapy (RT). Particle therapy has in general a 
considerable potential of reducing the irradiated volumes of 
healthy tissues, which is expected to have a positive effect 
on radiation-induced cancer. However, the carcinogenic 
effect of RT in the high dose region is uncertain, and is 
influenced by fractionation, radio-sensitivity, relative 
biological effects (RBE) as well as patient-specific patterns in 
the dose distributions. The aim of this study was therefore to 
estimate relative risks (RR) of secondary bladder and rectal 
cancer using dose distributions from x-ray, proton and 
carbon(C)-ion therapy as applied in contemporary clinical 
practice. We also included a model parameter scan to 
identify the influence of variations in typical values of these 
parameters. 
 
Material and Methods: Treatment plans for volumetric 
modulated arc therapy (VMAT, Eclipse), intensity-modulated 
proton therapy (IMPT; Eclipse) and C-ions (XiO-N) were 
generated for ten prostate cancer patients. For all three 
modalities, the primary clinical target volume included the 
prostate gland and the seminal vesicles, while technique 
specific boost volumes included the prostate only. Both VMAT 
and IMPT plans were prescribed to deliver 67.5 Gy(RBE) to 
the prostate and 60 Gy(RBE) to the seminal vesicles over 25 
fractions (assuming fiducial margin based set-up). The C-ion 
plans comprised 12 fractions with 34.4 Gy(RBE) to the total 
target volume and 51.6 Gy(RBE) to the boost volume (bony 
anatomy set-up). Physical dose distributions of the bladder 
and rectum were used to estimate the RR of radiation-
induced cancer (VMAT/IMPT and VMAT/C-ion) using the 
published malignant induction probability model (J Radiol 
Prot 2009). The mean RR results presented were calculated 
by sampling the dose distributions of all ten patients and 
previously published model input parameters with the listed 
confidence intervals (CI) (Table I). Subsequently a parameter 
scan was performed over a wide range of possible RBEs and 
radio-sensitivity (α and β) values. 
 
Results: The mean estimated RR (95% CI) of SC for VMAT/C-
ion were 1.31 (0.65, 2.18) for the bladder and 0.58 (0.41, 
0.80) for the rectum. Corresponding values for VMAT/IMPT 
were 1.73 (1.07, 2.39) and 1.11 (0.79, 1.45), respectively 
(Table I). The radio-sensitivity parameter α had the strongest 
influence on the RR for both the investigated organs; 
decreasing for increasing values of α (Fig 1). The β parameter 
influences the RR significantly only for very low α values 
(below about 0.2). 
 
 
 
